Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Contact Us Sitemap Sign In Register
Link to Homepage About AHAF
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Sign up for Email Notifications
If you would like to be notified when submission deadlines are announced please click on the link below.

Sign up for new RFP announcements and submission deadline notifications.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research funding through the American Health Assistance Foundation (www.ahaf.org). Please follow instructions on the notification emails for removal requests.
 
AHAF Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research
 

  

Alzheimer's Disease Research - Current Award

Dr. Jerry Chi-Ping Yin

Jerry Chi-Ping Yin, Ph.D.

Board of Regents of the University of Wisconsin System
Madison, WI

Title: Sleep And The Suppression Of Abeta-Mediated Phenotypes
Non-Technical Title: Sleep And Alzheimer's Disease

Duration: April 1, 2009 - March 31, 2011
Award Type: Pilot
Award Amount: $300,000


Summary:

Because of the rapid life spans and small size, fruit flies are used by many biologists to study complex genetics. In a fruit-fly model for Alzheimer's disease, sleep is disrupted at birth, preceding all of the other symptoms. Can increasing sleep, or decreasing the stresses of wakefulness, improve some of the later-onset disease symptoms? We will use pharmacological and genetic approaches to answer this question.

Details:

In a fruit-fly that has genetic similarities to Alzheimer's disease, disrupted sleep begins at birth. Other symptoms of Alzheimer's disease occur later in the life of the fly. Is it possible that the sleep defects partially cause or worsen the later symptoms? To answer this question, we will use a pharmacological approach and a genetic one to "enhance" sleep, and ask if it decreases the severity of later-onset symptoms. We are challenging the normally assumed progression of Alzheimer's disease. Normally, it is thought that the disease state leads to sleep disruptions, and these occur at the same time as some of the other late-onset symptoms. Our data suggests that sleep is disrupted beginning early in the life of the fly, and we will test if these sleep disturbances contribute to the later problems in disease progression. If this is true in humans, sleep medications could be given to patients early in the disease, including those with mild cognitive impairment. We are studying whether this approach might be a way to slow down or prevent disease progression. The specific aims of this proposal are: 1. Does a sleep drug prevent or improve later-onset symptoms of AD? 2. Does decreasing the stresses of wakefulness prevent or improve later-onset symptoms of AD? 3. Do molecular markers of the unfolded protein response increase in AD, and do they decrease if we are able to suppress later-onset symptoms?